Clinical Trials Logo
  1. Home
  2. Localized Prostate Cancer
  3. NCT03315754

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Localized Prostate Cancer Clinical Trial

Official title:
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.

Clinical Trial Summary

Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP in men with prostate cancer Gleason score 7(3+4).

Clinical Trial Description

This is a single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. The primary objective of the study is to evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP. Men with Gleason score 7 (3+4) prostate cancer on one half of the prostate will receive TOOKAD® Soluble VTP under general anesthesia. Treatment will consist in hemiablation procedure designed to destroy the lobe of the prostate gland that contains the Gleason score 7 (3+4) cancer. Afterwards, patients will be followed for 5 years (60 months) with clinical evaluation, questionnaires on QOL, erectile and urinary functions, and PSA testing. In addition, treatment outcomes will be assessed based on prostate biopsy results at 3, 12, 24, 36, 48 and 60 months after the TOOKAD® Soluble treatment. All patients will undergo biopsy at 3 and 12 months. If the Month 3 biopsy is positive for any cancer, patients will be allowed a single re-treatment by TOOKAD® Soluble VTP to one or both lobes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03315754
Study type Interventional
Source Steba Biotech S.A.
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 2, 2017
Completion date November 2, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03996005 - MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer N/A
Withdrawn NCT02159690 - A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Phase 2
Completed NCT00196781 - Treatment Decision Making in Early-Stage Prostate Cancer Phase 3
Recruiting NCT03821246 - Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Phase 2
Active, not recruiting NCT03814252 - Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer N/A
Completed NCT01931046 - Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Phase 1/Phase 2
Completed NCT01714219 - Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy N/A
Recruiting NCT05010343 - Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer Phase 2
Recruiting NCT06325995 - Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer N/A
Recruiting NCT06051942 - PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs N/A
Completed NCT02297386 - [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer Phase 1
Not yet recruiting NCT06117059 - The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance N/A
Withdrawn NCT04225299 - Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer Phase 3
Recruiting NCT06054867 - PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System N/A
Active, not recruiting NCT02435472 - Active Surveillance Exercise Clinical Trial N/A
Completed NCT00717613 - Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting N/A
Completed NCT02662673 - Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device N/A
Recruiting NCT05155046 - 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Phase 2
Completed NCT01902680 - Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant. Phase 2
Recruiting NCT00651417 - Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue Phase 2